Prostate cancer metastatic Trials in Madrid, Spain
Conditions / Prostate cancer metastatic / Madrid, Spain
Prostate cancer metastatic is a medical condition with active clinical research programs worldwide.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01322490 | A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer | COMPLETED | PHASE3 |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | RECRUITING | PHASE3 |
| NCT04916613 | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) | RECRUITING | — |
| NCT02933801 | ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | TERMINATED | PHASE2 |
| NCT02485691 | Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent | COMPLETED | PHASE4 |
| NCT03569241 | PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04916613 | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) | RECRUITING | — |
| NCT01254279 | Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen | COMPLETED | PHASE3 |
| NCT01360840 | EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | COMPLETED | PHASE2 |
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | COMPLETED | PHASE1 |